ImmunityBio

IBRX

Market cap $5.44B

Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.

ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma with one of its next-gen therapies.

ImmunityBio Inc. (NASDAQ: IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.

Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ: IBRX) just delivered one.

Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-NK cell therapy in Waldenström non-Hodgkin's lymphoma, adding to recent momentum driven by strong sales growth for its approved immunotherapy Anktiva. ImmunityBio said on Friday that follow-up from its ongoing Phase 1/2 QUILT-106 study demonstrated sustained complete responses lasting up to 15 months in evaluable patients, with 100% disease control observed to date.

Traders typically look for heavily shorted stocks for two main reasons: either to bet on a decline in the company's value or to profit from a short squeeze.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity natural killer (NK) cell therapy engineered to express a CD19-specifc chimeric antigen receptor (CAR) used in combi.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005. Enrollment has exceeded internal expectations and is now over 85% complete, with full enrollment of the planned study population anticipated by Q2 2026. Based on the current enrollment trajectory, ImmunityBio anticipates submitting a biologics license application (.

The shares have climbed on every trading day so far in 2026. The streak looks set to continue.